BRCA1-IN-2
BRCA1-IN-2 (compound 15) is a cell-permeable protein-protein interaction (PPI) inhibitor for BRCA1 with an IC50 of 0.31 μM and a Kd of 0.3 μM, which shows antitumor activities via the disruption of BRCA1 (BRCT) 2/protein interactions[1].
Product Specifications
CAS Number
1622262-55-8
UNSPSC
12352005
Target
PARP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/brca1-in-2.html
Purity
98.12
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N[C@@H](COP(O)(O)=O)C(NCC(NCCCCC1=CC=CC=C1)=O)=O)CCC2=CNC3=C2C=CC=C3
Molecular Formula
C26H33N4O7P
Molecular Weight
544.54
References & Citations
[1]Na Z, et al. Protein-Protein Interaction Inhibitors of BRCA1 Discovered Using Small Molecule Microarrays. Methods Mol Biol. 2017;1518:139-156.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Dalotuzumab Biosimilar - Research Grade
Polyclonal Anti-Drosophila melanogaster (Fruit fly) CG11084 Antibody, Cy3 Conjugate
ATG10, NT (APG10, APG10L, DKFZp586I0418, FLJ13954, pp12616, APG10 autophagy 10-like, APG10-like, autophagy-related protein 10) (MaxLight 650)
ATG10, NT (APG10, APG10L, DKFZp586I0418, FLJ13954, pp12616, APG10 autophagy 10-like, APG10-like, autophagy-related protein 10) (MaxLight 650)
